Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1605786A proof-of-concept study in active ulcerative colitis
NL-OMON35581Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing GSK1605786A with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Planned start Nov 2011; status: withdrawn.
02
Drugs
vercirnon
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON35581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35581.